Back to News
Sep 16, 2025 12:00 PM

Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19.

The update follows a media report on Friday that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine Adverse Event Reporting System.

The data from an ongoing Phase 4 trial evaluating the safety, tolerability, and immunogenicity of the 2025-2026 formula of Spikevax showed, on average, greater than an 8-fold increase in neutralizing antibodies against the LP.8.1 variant in individuals 12 through 64 years with at least one underlying condition and all adults 65 years of age and older.

Also Read: